Protocol Feasibility Committee


Composition

Chair

Dr. S. Kersting (Haga ziekenhuis, Den Haag)

Vice-chair

Dr. P. Westerweel (ASZ, Dordrecht)

Members

Hematologists
Dr. R. Brouwer (RdGG, Delft)
Dr. M. van Gelder (MUMC, Maastricht)
Dr. J. Janssen (AmsterdamUMC - VUMC, Amsterdam)
Dr. M. Minnema (UMCUtrecht, Utrecht)
(Research) nurses
A. Kramer (AmsterdamUMC – VUMC, Amsterdam)
J. van Deursen (MaximaMC, Eindhoven)
I. van Hout (Jeroen Bosch ziekenhuis, Den Bosch)
K. Beunen (Rijnstate, Arnhem)
E. Strijbosch (Radboudumc, Nijmegen)
E. Coenen (Radboudumc, Nijmegen)
L. Homans (Gelderse Vallei, Ede)
S. Hendriks (AmsterdamUMC, Amsterdam)
D. Verwindt (AmsterdamUMC, Amsterdam)
Trial consultants
B. van Haren (Radboudumc, Nijmegen)
A. Reitsma (Antonius ziekenhuis - Nieuwegein)
K. Nijssen (UMCU, Utrecht)
S. Klein (AmsterdamUMC - AMC, Amsterdam)
S. Silvis (MaximaMC, Eindhoven)
IKNL
H. Keles (IKNL, Utrecht)
M. van Hövell (IKNL, Utrecht)
H. Dijcker-vd Linden (IKNL, Utrecht)
Data Managers
I. Versteegden (AmsterdamUMC - Vumc, Amsterdam)
I. Gobbens (ErasmusMC, Rotterdam)
Pharmacists
A. Sobels (Haga ziekenhuis, Den Haag)

Advisors

Members of HOPP (Hematon research patient participation)


Key objectives of working group

The key objectives of this working group are:

  • Adjusting new study documents and protocols with the aim of successful start and execution of HOVON studies in the different hospitals (echelon A to D)

Tasks

  • The PUC reviews the protocol, CRF and ICF on practical feasibility before it is submitted to the METC and KWF.
  • Next to the above the PUC also reviews lab manuals, central review manuals and CRF instructions.
  • Only studies for which HOVON is primary sponsor, will be reviewed by the PUC. 

 

 

This content is restricted. Please log in.
This content is restricted. Please log in.
Up